[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588672":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":32,"id":59,"slug":32,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":32,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":32,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":32,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A1","EXPERIMENTAL","Dose escalation will be conducted using accelerated titration and traditional 3+3 design. Dose Escalation Level includes 12 levels, QW IV. Dose extension will be carried out at the selected level.",[13],"Drug: SSS59",{"label":15,"type":10,"description":16,"interventionNames":17},"Part A2","Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level includes 12 levels, Q2W IV. Dose extension will be carried out at the selected level.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part A3","Dose extension will be carried out at the selected dose level, Q3W, IV.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Part B","Indication extension will be carried out at the selected level.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","SSS59","A humanized antibody targeting MUC17",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Qi Li, MD","CONTACT","86+13818207333","Leeqi2001@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":32,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Shanghai First People's Hospital","RECRUITING","Shanghai","Shanghai Municipality","China",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":55,"phoneExt":32,"email":56},"Wenqian Geng","86+021-36126254","shiyilunli@sina.com",{"type":58,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100588672",false,"NCT06944444","A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Histologically and\u002For cytologically documented local advanced or recurrent or metastatic malignancies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Any remaining AEs \\> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Underwent major surgery within 4 weeks prior to first dosing.\n* The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":69,"type":70},154,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.",[76],"Malignant Tumors","2025-04-27",{"date":79,"type":80},"2025-04-29","ACTUAL",{"date":77,"type":80},{"date":83,"type":70},"2027-12-31",{"name":5,"class":6},1]